Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET
Company Participants
Louise Wilkie - Vice President, Investor Relations and Corporate Communications
Sandy Macrae - Chief Executive Officer
Nathalie Dubois-Stringfellow - Chief Development Officer
Prathyusha Duraibabu - Senior Vice President, Chief Financial Officer & Principal Accounting Officer
Conference Call Participants
Gena Wang - Barclays
Maury Raycroft - Jefferies
Luca Issi - RBC Capital Markets
Ritu Baral - TD Cowen
Operator
Good afternoon and welcome to the Sangamo Therapeutics Third Quarter 2024 Teleconference Call. Please be advised that today's conference is being recorded.
I would now like to turn the conference over to your speaker today, Louise Wilkie, Vice President of Investor Relations and Corporate Communications. Please go ahead.
Louise Wilkie
Thank you. Good afternoon, everyone. Thank you for joining us on the call today.
On this call are several members of the Sangamo executive leadership team, including Sandy Macrae, Chief Executive Officer; Nathalie Dubois-Stringfellow, Chief Development Officer; and Prathyusha Duraibabu, Chief Financial Officer. Slides from our corporate presentation can be found on our website sangamo.com under the Presentations page of the Investors and Media section.
This call includes forward-looking statements regarding Sangamo’s current expectations. These statements include but are not limited to statements relating to Sangamo's cash runway, plans to obtain additional capital and ability to continue to operate as a going concern. The therapeutic and commercial potential of Sangamo's product candidates and technologies, Sangamo's ability to earn and receive payments from it’s collaboration and license agreements, including the Genentech and Pfizer agreements, Sangamo's expectations regarding new collaboration and license agreements, the anticipated plans and timelines of Sangamo and its collaborators for clinical trials, clinical data presentations and releases, regulatory submissions and regulatory approvals, upcoming catalysts and milestones and other statements that are not historical facts.
Actual results may differ materially from what we discussed today. These statements are subject to certain risks and uncertainties that are discussed in our filings with the SEC, specifically in our annual report on Form 10-K for the fiscal year ended December 31, 2023, as supplemented by Sangamo's quarterly report on Form 10-Q for the quarter ended September 30, 2024 and subsequent filings and reports that Sangamo makes from time-to-time with the SEC. The forward-looking statements stated today are made as of today and we undertake no duty to update such information except as required by law. Please note that all forward-looking statements about our future plans and expectations are subject to our ability to secure adequate additional funding.